ADXN Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Addex Therapeutics Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF0.069 |
52 Week High | CHF0.26 |
52 Week Low | CHF0.036 |
Beta | 1.82 |
1 Month Change | 0.59% |
3 Month Change | 0.88% |
1 Year Change | -40.35% |
3 Year Change | -95.71% |
5 Year Change | -95.69% |
Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
Mar 03Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
May 11Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)
Jun 10Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Mar 07Shareholder Returns
ADXN | CH Biotechs | CH Market | |
---|---|---|---|
7D | 1.5% | 5.5% | 0.7% |
1Y | -40.3% | 35.1% | 1.7% |
Return vs Industry: ADXN underperformed the Swiss Biotechs industry which returned 35.6% over the past year.
Return vs Market: ADXN underperformed the Swiss Market which returned 2.1% over the past year.
Price Volatility
ADXN volatility | |
---|---|
ADXN Average Weekly Movement | 23.1% |
Biotechs Industry Average Movement | 7.2% |
Market Average Movement | 3.5% |
10% most volatile stocks in CH Market | 6.7% |
10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: ADXN's share price has been volatile over the past 3 months.
Volatility Over Time: ADXN's weekly volatility has increased from 17% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
ADXN fundamental statistics | |
---|---|
Market cap | CHF8.80m |
Earnings (TTM) | -CHF10.56m |
Revenue (TTM) | CHF1.65m |
5.3x
P/S Ratio-0.8x
P/E RatioIs ADXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ADXN income statement (TTM) | |
---|---|
Revenue | CHF1.65m |
Cost of Revenue | CHF6.94m |
Gross Profit | -CHF5.29m |
Other Expenses | CHF5.27m |
Earnings | -CHF10.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jun 06, 2024
Earnings per share (EPS) | -0.082 |
Gross Margin | -321.08% |
Net Profit Margin | -640.91% |
Debt/Equity Ratio | 0% |
How did ADXN perform over the long term?
See historical performance and comparison